Plastic Meets Biology

02 Science

Our lead therapeutic candidate is composed of four engineered enzyme variants optimized for broad-spectrum microplastic degradation within the human body.

Microplastics are increasingly recognized as bioactive pollutants, not inert bystanders. Once they enter the bloodstream and tissues, they interfere with cellular function, trigger oxidative stress, impair hormonal signaling, and contribute to chronic inflammation. Their presence has been linked to chronic inflammation, endocrine disruption, metabolic dysfunction, and now possibly cancer, yet no therapeutic options currently exist to address their accumulation in the human body.

At Elora, we’re developing a first-of-its-kind therapeutic: a systemically delivered enzyme composition designed to degrade microplastics in vivo. Unlike environmental enzymes, ours are optimized for human physiology, stable in serum, active at physiological pH, and capable of transforming synthetic polymers into small, excretable monomers.

Our current formulation targets four high-prevalence polymers in the human body: PET, PE, PP, and PS. In collaboration with leading academic partners, we are conducting early-stage validation studies to assess enzyme activity, stability, and biocompatibility in biologically relevant systems.

This is molecular intervention at the root cause. This is science built to address a modern, synthetic threat.